Neurosurgical Interventions for Cerebral Metastases of Solid Tumors.


Journal

Deutsches Arzteblatt international
ISSN: 1866-0452
Titre abrégé: Dtsch Arztebl Int
Pays: Germany
ID NLM: 101475967

Informations de publication

Date de publication:
10 03 2023
Historique:
received: 13 05 2022
revised: 13 05 2022
accepted: 20 12 2022
medline: 1 5 2023
pubmed: 19 1 2023
entrez: 18 1 2023
Statut: ppublish

Résumé

Metastases are the most common malignant tumors affecting the central nervous system and occur in 20-40 percent of patients with solid systemic tumors. The aim of this review is to discuss the role of neurosurgical procedures in a modern, multidisciplinary treatment approach. An expert panel of neurosurgeons, neurologists, and radio-oncologists conducted a selective literature review on neu - rosurgical interventions for the diagnosis and treatment of cerebral metastases. Original articles, meta-analyses, and systematic reviews were included. There is a lack of prospective randomized studies. Based on retrospective case series, international guidelines recommend the harvesting (if required, stereotactically guided) of tissue for histological and molecular diagnosis in cases of unknown or possibly competing underlying systemic malignant diseases, in cases of suspected tumor recurrence, and with regard to the evaluation of targeted therapies taking into account molecular heterogeneity of primary and secondary tumors. Surgical resection is particularly valuable for the treatment of up to three space-occupying cerebral metastases, especially to achieve clinical stabilization to allow further non-surgical treatment. For cystic metastasis, a combination of stereotactic puncture and radiotherapy may be useful. Meningeal carcinomatosis can be treated with intrathecal medication via an intraventricular catheter system. Ventriculo-peritoneal shunts represents an effective treatment option for patients with tumor-associated hydrocephalus. Neurosurgical procedures are of central importance in the multimodal treatment of cerebral metastases. The indications for neurosurgical interventions will be refined in the light of more effective radiation techniques and systemic treatments with new targeted therapeutic approaches and immunotherapies on the horizon.

Sections du résumé

BACKGROUND
Metastases are the most common malignant tumors affecting the central nervous system and occur in 20-40 percent of patients with solid systemic tumors. The aim of this review is to discuss the role of neurosurgical procedures in a modern, multidisciplinary treatment approach.
METHODS
An expert panel of neurosurgeons, neurologists, and radio-oncologists conducted a selective literature review on neu - rosurgical interventions for the diagnosis and treatment of cerebral metastases. Original articles, meta-analyses, and systematic reviews were included.
RESULTS
There is a lack of prospective randomized studies. Based on retrospective case series, international guidelines recommend the harvesting (if required, stereotactically guided) of tissue for histological and molecular diagnosis in cases of unknown or possibly competing underlying systemic malignant diseases, in cases of suspected tumor recurrence, and with regard to the evaluation of targeted therapies taking into account molecular heterogeneity of primary and secondary tumors. Surgical resection is particularly valuable for the treatment of up to three space-occupying cerebral metastases, especially to achieve clinical stabilization to allow further non-surgical treatment. For cystic metastasis, a combination of stereotactic puncture and radiotherapy may be useful. Meningeal carcinomatosis can be treated with intrathecal medication via an intraventricular catheter system. Ventriculo-peritoneal shunts represents an effective treatment option for patients with tumor-associated hydrocephalus.
CONCLUSION
Neurosurgical procedures are of central importance in the multimodal treatment of cerebral metastases. The indications for neurosurgical interventions will be refined in the light of more effective radiation techniques and systemic treatments with new targeted therapeutic approaches and immunotherapies on the horizon.

Identifiants

pubmed: 36650742
pii: arztebl.m2022.0410
doi: 10.3238/arztebl.m2022.0410
pmc: PMC10201951
doi:
pii:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

162-169

Références

J Clin Oncol. 2022 Feb 10;40(5):492-516
pubmed: 34932393
Front Oncol. 2022 Mar 14;12:847110
pubmed: 35359380
Front Neurol. 2022 Mar 30;13:822362
pubmed: 35432168
J Neurosurg. 2009 Apr;110(4):730-6
pubmed: 19072310
Oncologist. 2019 May;24(5):671-679
pubmed: 30796152
Cancer Med. 2020 Oct;9(20):7503-7510
pubmed: 32858763
Strahlenther Onkol. 2021 Jul;197(7):601-613
pubmed: 33884441
Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
Neurosurg Clin N Am. 2020 Oct;31(4):575-587
pubmed: 32921353
Neurooncol Adv. 2021 Nov 10;3(1):vdab162
pubmed: 34859226
N Engl J Med. 1990 Feb 22;322(8):494-500
pubmed: 2405271
J Invest Dermatol. 2015 Dec;135(12):3078-3085
pubmed: 26083553
Acta Neurochir (Wien). 2017 Apr;159(4):751-754
pubmed: 28154933
Lancet Oncol. 2015 Nov;16(15):e534-e542
pubmed: 26545842
Radiat Oncol. 2011 May 15;6:48
pubmed: 21575163
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8
pubmed: 10802351
Cancer Discov. 2015 Nov;5(11):1164-1177
pubmed: 26410082
Cancer. 2020 Oct 1;126(19):4341-4352
pubmed: 32678971
Neuro Oncol. 2019 May 6;21(5):585-595
pubmed: 30615138
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
J Neurosurg. 1993 Aug;79(2):210-6
pubmed: 8331402
Mol Clin Oncol. 2015 Nov;3(6):1381-1386
pubmed: 26807251
J Clin Oncol. 2020 Nov 10;38(32):3773-3784
pubmed: 32931399
Dtsch Arztebl Int. 2021 Nov 12;(Forthcoming):
pubmed: 34730083
J Neurooncol. 2008 May;87(3):299-307
pubmed: 18157648
Pharmacogenomics. 2017 Apr;18(6):585-594
pubmed: 28290769
Trends Cancer. 2021 Sep;7(9):809-822
pubmed: 33722479
Eur J Cancer. 2022 Feb;162:170-181
pubmed: 34998049
Front Oncol. 2022 May 04;12:869764
pubmed: 35600394
Ann Oncol. 2021 Nov;32(11):1332-1347
pubmed: 34364998
J Neurosurg. 2017 Mar;126(3):698-707
pubmed: 27128588
World Neurosurg. 2020 Nov;143:e365-e373
pubmed: 32730972
Eur J Cancer. 2021 Oct;156:93-108
pubmed: 34425408
World Neurosurg. 2016 Nov;95:178-189
pubmed: 27506410
ESMO Open. 2020 Aug;5(4):
pubmed: 32747372
Cancer. 1996 Oct 1;78(7):1470-6
pubmed: 8839553
Acta Neuropathol. 2014 Dec;128(6):879-91
pubmed: 25287912
Neurosurgery. 2020 Dec 15;88(1):E67-E72
pubmed: 32823285
Brain Sci. 2021 Jan 18;11(1):
pubmed: 33477588
Breast Cancer Res. 2012 Aug 16;14(4):R119
pubmed: 22898337
Lancet Oncol. 2010 Sep;11(9):871-9
pubmed: 20598636
Handb Clin Neurol. 2018;149:27-42
pubmed: 29307358
BMC Cancer. 2020 Apr 17;20(1):331
pubmed: 32303195
J Neurosurg. 2021 Oct 29;:1-7
pubmed: 34715653
Neuro Oncol. 2021 Apr 12;23(4):661-676
pubmed: 33068418
BMC Cancer. 2022 Mar 15;22(1):275
pubmed: 35291972
Lancet Oncol. 2017 Aug;18(8):1040-1048
pubmed: 28687375
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120803
Neurology. 1996 Jun;46(6):1674-7
pubmed: 8649568
Neuro Oncol. 2020 Jan 11;22(1):84-93
pubmed: 31412120
Acta Neurochir (Wien). 2015 Jun;157(6):905-10; discussion 910-1
pubmed: 25845550
Neurosurgery. 2005 May;56(5):1021-34; discussion 1021-34
pubmed: 15854250
J Nucl Med. 2021 Apr;62(4):464-470
pubmed: 32887757
Br J Neurosurg. 2016;30(1):43-8
pubmed: 25958957
Neurosurg Rev. 2021 Feb;44(1):301-307
pubmed: 31900737
ESMO Open. 2016 Mar 16;1(2):e000024
pubmed: 27843591
Front Oncol. 2021 May 05;11:662943
pubmed: 34026641
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34215688
Acta Neurochir (Wien). 2013 Oct;155(10):1823-32
pubmed: 23913109
Front Oncol. 2018 Nov 20;8:509
pubmed: 30524956
Neuro Oncol. 2021 Sep 1;23(9):1447-1456
pubmed: 33908612
World J Surg Oncol. 2019 Mar 27;17(1):59
pubmed: 30917830
Neurology. 2005 May 10;64(9):1625-7
pubmed: 15883329
Neurology. 1998 Feb;50(2):438-44
pubmed: 9484369
J Neurosurg. 2015 May;122(5):1132-43
pubmed: 25794344
J Neurosurg. 1997 Aug;87(2):327-30
pubmed: 9254101
J Neurooncol. 2017 Aug;134(1):55-64
pubmed: 28567587
Neuro Oncol. 2013 Dec;15(12):1664-72
pubmed: 24084410
Neuro Oncol. 2019 Aug 5;21(8):1049-1059
pubmed: 30828727
Neuro Oncol. 2020 Nov 26;22(11):1568-1579
pubmed: 32598442
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):618-630
pubmed: 30395902
Acta Neurochir (Wien). 2013 Mar;155(3):389-97
pubmed: 23325516
J Neurosurg. 2011 Jun;114(6):1609-16
pubmed: 21142749
Cancer Manag Res. 2019 Feb 20;11:1753-1763
pubmed: 30858728
Ann Neurol. 1993 Jun;33(6):583-90
pubmed: 8498838
Clin Oncol (R Coll Radiol). 2011 Nov;23(9):646-51
pubmed: 21592754

Auteurs

Niklas Thon (N)

Department of Neurosurgery, Ludwig Maximillian University of Munich, Munich; German Cancer Consortium, Partner Site Munich, Munich; Department of Radiation Oncology, University Hospital, LMU Munich, Munich; Dr. Senckenberg Institute of Neurooncology, Center of Neurology and Neurosurgery, Frankfurt am Main; German Cancer Consortium, Partner Site Frankfurt, Frankfurt; University Cancer Center (UCT) Frankfurt, Frankfurt am Main; Department of Neurology, Klinikum der Munich University Hospital, Munich.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH